Cargando…
The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants
As the fifth variant of concern of the SARS‐CoV‐2 virus, the Omicron variant (B.1.1.529) has quickly become the dominant type among the previous circulating variants worldwide. During the Omicron wave, several subvariants have emerged, with some exhibiting greater infectivity and immune evasion, acc...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10015854/ https://www.ncbi.nlm.nih.gov/pubmed/36938325 http://dx.doi.org/10.1002/mco2.239 |
_version_ | 1784907285025259520 |
---|---|
author | Ao, Danyi He, Xuemei Hong, Weiqi Wei, Xiawei |
author_facet | Ao, Danyi He, Xuemei Hong, Weiqi Wei, Xiawei |
author_sort | Ao, Danyi |
collection | PubMed |
description | As the fifth variant of concern of the SARS‐CoV‐2 virus, the Omicron variant (B.1.1.529) has quickly become the dominant type among the previous circulating variants worldwide. During the Omicron wave, several subvariants have emerged, with some exhibiting greater infectivity and immune evasion, accounting for their fast spread across many countries. Recently, two Omicron subvariants, BQ.1 and XBB lineages, including BQ.1.1, XBB.1, and XBB.1.5, have become a global public health issue given their ability to escape from therapeutic monoclonal antibodies and herd immunity induced by prior coronavirus disease 2019 (COVID‐19) vaccines, boosters, and infection. In this respect, XBB.1.5, which has been established to harbor a rare mutation F486P, demonstrates superior transmissibility and immune escape ability compared to other subvariants and has emerged as the dominant strain in several countries. This review provides a comprehensive overview of the epidemiological features, spike mutations, and immune evasion of BQ.1 and XBB lineages. We expounded on the mechanisms underlying mutations and immune escape from neutralizing antibodies from vaccinated or convalescent COVID‐19 individuals and therapeutic monoclonal antibodies (mAbs) and proposed strategies for prevention against BQ.1 and XBB sublineages. |
format | Online Article Text |
id | pubmed-10015854 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100158542023-03-16 The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants Ao, Danyi He, Xuemei Hong, Weiqi Wei, Xiawei MedComm (2020) Perspective As the fifth variant of concern of the SARS‐CoV‐2 virus, the Omicron variant (B.1.1.529) has quickly become the dominant type among the previous circulating variants worldwide. During the Omicron wave, several subvariants have emerged, with some exhibiting greater infectivity and immune evasion, accounting for their fast spread across many countries. Recently, two Omicron subvariants, BQ.1 and XBB lineages, including BQ.1.1, XBB.1, and XBB.1.5, have become a global public health issue given their ability to escape from therapeutic monoclonal antibodies and herd immunity induced by prior coronavirus disease 2019 (COVID‐19) vaccines, boosters, and infection. In this respect, XBB.1.5, which has been established to harbor a rare mutation F486P, demonstrates superior transmissibility and immune escape ability compared to other subvariants and has emerged as the dominant strain in several countries. This review provides a comprehensive overview of the epidemiological features, spike mutations, and immune evasion of BQ.1 and XBB lineages. We expounded on the mechanisms underlying mutations and immune escape from neutralizing antibodies from vaccinated or convalescent COVID‐19 individuals and therapeutic monoclonal antibodies (mAbs) and proposed strategies for prevention against BQ.1 and XBB sublineages. John Wiley and Sons Inc. 2023-03-15 /pmc/articles/PMC10015854/ /pubmed/36938325 http://dx.doi.org/10.1002/mco2.239 Text en © 2023 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Perspective Ao, Danyi He, Xuemei Hong, Weiqi Wei, Xiawei The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants |
title | The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants |
title_full | The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants |
title_fullStr | The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants |
title_full_unstemmed | The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants |
title_short | The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants |
title_sort | rapid rise of sars‐cov‐2 omicron subvariants with immune evasion properties: xbb.1.5 and bq.1.1 subvariants |
topic | Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10015854/ https://www.ncbi.nlm.nih.gov/pubmed/36938325 http://dx.doi.org/10.1002/mco2.239 |
work_keys_str_mv | AT aodanyi therapidriseofsarscov2omicronsubvariantswithimmuneevasionpropertiesxbb15andbq11subvariants AT hexuemei therapidriseofsarscov2omicronsubvariantswithimmuneevasionpropertiesxbb15andbq11subvariants AT hongweiqi therapidriseofsarscov2omicronsubvariantswithimmuneevasionpropertiesxbb15andbq11subvariants AT weixiawei therapidriseofsarscov2omicronsubvariantswithimmuneevasionpropertiesxbb15andbq11subvariants AT aodanyi rapidriseofsarscov2omicronsubvariantswithimmuneevasionpropertiesxbb15andbq11subvariants AT hexuemei rapidriseofsarscov2omicronsubvariantswithimmuneevasionpropertiesxbb15andbq11subvariants AT hongweiqi rapidriseofsarscov2omicronsubvariantswithimmuneevasionpropertiesxbb15andbq11subvariants AT weixiawei rapidriseofsarscov2omicronsubvariantswithimmuneevasionpropertiesxbb15andbq11subvariants |